

**Ohio Department of Job and Family Services (ODJFS)**  
**Drug Utilization Review (DUR) Board**  
**Quarterly Meeting**  
**November 13, 2012**

The quarterly meeting of the ODJFS DUR Board was called to order at 12:06 PM in Room East B, 31st floor of the Riffe Building, 77 S. High St. Columbus, Ohio. David Brookover, RPh, presided. The following Board members were present:

David Brookover, RPh, Chair  
Thomas Gretter, MD  
Robert Kubasak, RPh  
Kevin Mitchell, RPh  
J. Layne Moore, MD  
Donald Sullivan, RPh, PhD

Also present were Margaret Scott, RPh, DUR Administrator; Mike Howcroft, RPh, Medicaid pharmacist, Jill Griffith, RPh, DUR Director; and Bob Cluxton, RPh, PharmD from the University Of Cincinnati College Of Pharmacy.

Reading, Correction & Approval of Previous Minutes:

The September 11th, 2012, DUR Board minutes were amended and approved. (1st D. Sullivan, 2nd R. Kubasak).

Health Plan Policy:

M. Scott gave the Health Plan Policy report: The ODJFS Office of Ohio Health Plans has been re-named the Office of Medical Assistance (OMA). OMA will be a separate cabinet-level agency by July 1, 2014. The new Preferred Drug List (PDL) became effective on October 1<sup>st</sup> with no problems reported. ODJFS continues to participate on the Cabinet Opiate Action Team. The State has also been working to address atypical antipsychotic use in children and in the elderly.

New Business:

M. Scott introduced Dr. Mary Applegate, Medicaid Medical Director. Dr. Applegate discussed the problem of over overprescribing atypical antipsychotics in children. The State has obtained \$1 million to address the problem. The money will be used to develop educational toolkits. The toolkits will provide drug information at appropriate technical levels to inform agency personnel working with children and their families and caregivers as well as inform the children and families themselves. Toolkits will also be developed for school educators and the justice system. It is anticipated that the DUR Board will oversee quarterly mailings to outlier prescribers aiming to reduce the use of: 1) antipsychotic medications in children less than six years of age; 2) concurrent use of two or more antipsychotic medications for longer than two months in kids less

than 18 years of age; and 3) use of four or more psychotropics at the same time. The letters will offer use of the Pediatric Psychiatry Network (PPN).

DUR Committee Report:

J. Griffith announced that the October DUR committee reviewed 1,448 the profiles of patients on duplicative long-acting stimulants. The November DUR Committee met this morning and edited the letter sets. The Board reviewed, discussed, edited and approved the letter sets.

Unfinished Business:

J. Griffith announced that the DUR committee will review the profiles of patients demonstrating excessive rescue inhaler use (with no evidence of a controller therapy). The DUR committee will also review duplicate inhaler use, defined as the use of combination inhalers containing a corticosteroid and a long-acting bronchodilator (Advair<sup>®</sup>, Dulera<sup>®</sup> or Symbicort<sup>®</sup>), concurrently with duplicative single-ingredient inhalers.

Announcements:

The first quarter DUR Board meeting is scheduled for noon on Tuesday, February 26<sup>th</sup>, location to be announced. The second quarter DUR Board meeting is scheduled for noon on Tuesday, May 21st, location to be announced.

Elections were held for Chair and Co-Chair. No changes were made this year. Chair David Brookover and Co-Chair Lenard Presutti were re-elected.

Adjournment:

D. Brookover adjourned the meeting at 1:06 PM.

Respectfully submitted:

---

Jill RK Griffith BS, PharmD, DUR Program Director